Available Clinical Trials

Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.

To inquire about participation in a clinical trial, please contact us at (804) 893-8717.

Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.

Search Clinical Trials

Select Category       or   
Displaying All Clinical Trials (21 - 30 of 46)
EFC 15858

SAR408701 versus docetaxel in previously treated, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-positive, metastatic nonsquamous non–small-cell lung cancer patients (CARMEN-LC03)

FAQs

What are clinical trials, and why are they important? Are there different types of cancer clinical trials? Who manages clinical …

SWOG 2001

A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases   …

Alliance 212102

Alliance Protocol A212102, “Blinded Reference Set for Multicancer Early Detection Blood Tests”   https://www.clinicaltrials.gov/ct2/show/NCT05334069?term=NCT05334069&draw=2&rank=1  

J2J-MC-JZLH (EMBER-4)

A Study of imlunestrant vs physician’s choice endocrine therapy as adjuvant treatment after 2 to 5 years of standard adjuvant …

SWOG LUNG-MAP

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

MK-3475-B49

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate …

NRG-GI008

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

NRG-BN011

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

NRG Oncology NRG-GU005

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer